F. Triana-Martínez, Pilar Picallos-Rabina, Sabela Da Silva-Álvarez, F. Pietrocola, S. Llanos, V. Rodilla, E. Soprano, Pablo Pedrosa, Alba Ferreirós, M. Barradas, F. Hernández-González, Marta Lalinde, Neus Prats, Cristina Bernadó, Patricia González, María Gómez, M. Ikonomopoulou, P. Fernández-Marcos, T. García-Caballero, P. del Pino, J. Arribas, A. Vidal, M. González-Barcia, M. Serrano, M. Loza, E. Domínguez, M. Collado
Nature Communications, 2019
Compounds with specific cytotoxic activity in senescent cells, or senolytics, support the causal involvement of senescence in aging and offer therapeutic interventions. Here we report the identification of Cardiac Glycosides (CGs) as a family of compounds with senolytic activity. CGs, by targeting the Na+/K+ATPase pump, cause a disbalanced electrochemical gradient within the cell causing depolarization and acidification. Senescent cells present a slightly depolarized plasma membrane and higher concentrations of H+, making them more susceptible to the action of CGs. These vulnerabilities can be exploited for therapeutic purposes as evidenced by the in vivo eradication of tumors xenografted in mice after treatment with the combination of a senogenic and a senolytic drug. The senolytic effect of CGs is also effective in the elimination of senescence-induced lung fibrosis. This experimental approach allows the identification of compounds with senolytic activity that could potentially be used to develop effective treatments against age-related diseases. Senolytic compounds have the ability to eliminate senescent cells from tissues and have been shown to be beneficial in various animal models of age-related diseases. Here the authors show that cardiac glycosides commonly used for heart diseases have senolytic properties in humanized mouse models of tumorigenesis and lung fibrosis.
Cited by 73 publications.
Field of study: Chemistry